0001835597false00018355972024-08-202024-08-20

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 20, 2024

 

 

PepGen Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-41374

85-3819886

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

321 Harrison Avenue

8th Floor

 

Boston, Massachusetts

 

02118

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (781) 797-0979

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common stock, par value $0.0001 per share

 

PEPG

 

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


Item 8.01 Other Events.

On August 20, 2024, PepGen Inc. (the “Company”) announced the appointment of Paul Streck, M.D., MBA, as the Company’s Executive Vice President, Head of Research & Development. A copy of the press release issued in connection with this announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits:

 

Exhibit Number

Description

99.1

Press release issued by PepGen Inc. on August 20, 2024

104

Cover Page Interactive Data Filed (embedded within the Inline XBRL document)

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

PEPGEN INC.

 

 

 

 

Date:

August 20, 2024

By:

/s/ Noel Donnelly

 

 

 

Noel Donnelly, Chief Financial Officer

 


img148377401_0.jpg 

 

PepGen Appoints Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development

BOSTON, August 20, 2024 -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development (R&D), effective immediately. Dr. Streck will join the PepGen Executive Team and will be responsible for leading the R&D organization.

 

“We are very pleased that Paul is joining PepGen at such an important time for the Company,” said James McArthur, Ph.D., President and CEO of PepGen. “Throughout his career, Paul has served in leadership roles across both large and small publicly traded biopharmaceutical companies, with notable accomplishments including five IND approvals, six global regulatory launches, and nine commercial product launches. This breadth of experience has equipped him with institutional knowledge that will be of extreme value to PepGen as we continue to advance our four active clinical trials and growing pipeline of preclinical candidates.”

 

Dr. Streck has more than 20 years of experience in drug development, regulatory, and medical affairs leadership. Most recently, he served as Chief Medical Officer at Albireo Pharma, a publicly traded rare disease biotechnology company acquired by Ipsen in March 2023. Previously, Dr. Streck was Chief Medical Officer at Arena Pharmaceuticals, a publicly traded immuno-inflammatory biotechnology company acquired by Pfizer in March 2022. Before that, he served as Chief Medical Officer at Alder Biopharmaceuticals, acquired by Lundbeck Pharmaceuticals in October 2020, and as the Chief Medical Officer of Insmed, advancing the company from clinical to commercial stage. Previous biopharmaceutical experience includes progressive roles at GSK, Shire, and Amgen, as well as 10 years in academic medical practice.

 

About PepGen

 

PepGen Inc. is a clinical-stage biotechnology company advancing the next-generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen’s Enhanced Delivery Oligonucleotide (EDO) platform is founded on over a decade of research and development and leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using


img148377401_0.jpg 

these EDO peptides, we are generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases.

 

For more information, please visit www.pepgen.com. Follow PepGen on LinkedIn and X.

 

Investor Contact
Dave Borah, CFA

SVP, Investor Relations and Corporate Communications

dborah@pepgen.com

Media Contact

Julia Deutsch

Lyra Strategic Advisory

Jdeutsch@lyraadvisory.com

 


v3.24.2.u1
Document And Entity Information
Aug. 20, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 20, 2024
Entity Registrant Name PepGen Inc.
Entity Central Index Key 0001835597
Entity Emerging Growth Company true
Entity File Number 001-41374
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 85-3819886
Entity Address, Address Line One 321 Harrison Avenue
Entity Address, Address Line Two 8th Floor
Entity Address, City or Town Boston
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02118
City Area Code (781)
Local Phone Number 797-0979
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period false
Title of 12(b) Security Common stock, par value $0.0001 per share
Trading Symbol PEPG
Security Exchange Name NASDAQ

PepGen (NASDAQ:PEPG)
Historical Stock Chart
From Oct 2024 to Oct 2024 Click Here for more PepGen Charts.
PepGen (NASDAQ:PEPG)
Historical Stock Chart
From Oct 2023 to Oct 2024 Click Here for more PepGen Charts.